#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=We noted a constant increase in the incidence of IE in Spain , principally because of a dramatic rise in the proportion of NIE concurrent with a decline in the percentage of CIE .
2-1	14-16	We	person	acc	ana	15-1
2-2	17-22	noted	_	_	_	_
2-3	23-24	a	abstract[3]	new[3]	coref	8-5[48_3]
2-4	25-33	constant	abstract[3]	new[3]	_	_
2-5	34-42	increase	abstract[3]	new[3]	_	_
2-6	43-45	in	abstract[3]	new[3]	_	_
2-7	46-49	the	abstract[3]|abstract[4]	new[3]|new[4]	coref	4-4[20_4]
2-8	50-59	incidence	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-9	60-62	of	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-10	63-65	IE	abstract[3]|abstract[4]|object	new[3]|new[4]|new	coref	7-9
2-11	66-68	in	abstract[3]	new[3]	_	_
2-12	69-74	Spain	abstract[3]|place	new[3]|new	coref	8-14
2-13	75-76	,	abstract[3]	new[3]	_	_
2-14	77-88	principally	abstract[3]|event[7]	new[3]|new[7]	coref	22-1[184_7]
2-15	89-96	because	abstract[3]|event[7]	new[3]|new[7]	_	_
2-16	97-99	of	abstract[3]|event[7]	new[3]|new[7]	_	_
2-17	100-101	a	abstract[3]|event[7]	new[3]|new[7]	_	_
2-18	102-110	dramatic	abstract[3]|event[7]	new[3]|new[7]	_	_
2-19	111-115	rise	abstract[3]|event[7]	new[3]|new[7]	_	_
2-20	116-118	in	abstract[3]|event[7]	new[3]|new[7]	_	_
2-21	119-122	the	abstract[3]|event[7]|abstract[8]	new[3]|new[7]|new[8]	_	_
2-22	123-133	proportion	abstract[3]|event[7]|abstract[8]	new[3]|new[7]|new[8]	_	_
2-23	134-136	of	abstract[3]|event[7]|abstract[8]	new[3]|new[7]|new[8]	_	_
2-24	137-140	NIE	abstract[3]|event[7]|abstract[8]|abstract	new[3]|new[7]|new[8]|new	coref	3-1
2-25	141-151	concurrent	abstract[3]|event[7]	new[3]|new[7]	_	_
2-26	152-156	with	_	_	_	_
2-27	157-158	a	event[10]	new[10]	coref	20-10[150_10]
2-28	159-166	decline	event[10]	new[10]	_	_
2-29	167-169	in	event[10]	new[10]	_	_
2-30	170-173	the	event[10]|abstract[11]	new[10]|new[11]	_	_
2-31	174-184	percentage	event[10]|abstract[11]	new[10]|new[11]	_	_
2-32	185-187	of	event[10]|abstract[11]	new[10]|new[11]	_	_
2-33	188-191	CIE	event[10]|abstract[11]|abstract	new[10]|new[11]|new	coref	3-6
2-34	192-193	.	_	_	_	_

#Text=NIE showed higher morbidity than CIE , as elderly patients were the most affected group .
3-1	194-197	NIE	abstract	giv	coref	5-27[34_0]
3-2	198-204	showed	_	_	_	_
3-3	205-211	higher	abstract[14]	new[14]	_	_
3-4	212-221	morbidity	abstract[14]	new[14]	_	_
3-5	222-226	than	_	_	_	_
3-6	227-230	CIE	abstract	giv	coref	4-6
3-7	231-232	,	_	_	_	_
3-8	233-235	as	_	_	_	_
3-9	236-243	elderly	person[16]	new[16]	coref	3-12[17_16]
3-10	244-252	patients	person[16]	new[16]	_	_
3-11	253-257	were	_	_	_	_
3-12	258-261	the	person[17]	giv[17]	coref	11-10[78_17]
3-13	262-266	most	person[17]	giv[17]	_	_
3-14	267-275	affected	person[17]	giv[17]	_	_
3-15	276-281	group	person[17]	giv[17]	_	_
3-16	282-283	.	_	_	_	_

#Text=The North reported the highest CIE incidence .
4-1	284-287	The	organization[18]	new[18]	coref	27-15[223_18]
4-2	288-293	North	organization[18]	new[18]	_	_
4-3	294-302	reported	_	_	_	_
4-4	303-306	the	abstract[20]	giv[20]	_	_
4-5	307-314	highest	abstract[20]	giv[20]	_	_
4-6	315-318	CIE	abstract|abstract[20]	giv|giv[20]	coref	5-30
4-7	319-328	incidence	abstract[20]	giv[20]	_	_
4-8	329-330	.	_	_	_	_

#Text=Cox regression analysis revealed that age , Charlson index , hemodialysis , shock , heart failure , and stroke were independent risk factors of mortality for both NIE and CIE .
5-1	331-334	Cox	abstract[21]|abstract[22]	new[21]|new[22]	_	_
5-2	335-345	regression	abstract[21]|abstract[22]	new[21]|new[22]	_	_
5-3	346-354	analysis	abstract[22]	new[22]	_	_
5-4	355-363	revealed	_	_	_	_
5-5	364-368	that	_	_	_	_
5-6	369-372	age	abstract	new	coref	22-27[190_0]
5-7	373-374	,	_	_	_	_
5-8	375-383	Charlson	person|abstract[25]	new|new[25]	coref|coref	21-7|21-5[166_25]
5-9	384-389	index	abstract[25]	new[25]	_	_
5-10	390-391	,	_	_	_	_
5-11	392-404	hemodialysis	abstract	new	_	_
5-12	405-406	,	_	_	_	_
5-13	407-412	shock	event	new	coref	21-39
5-14	413-414	,	_	_	_	_
5-15	415-420	heart	object|event[29]	new|new[29]	coref|coref	21-41|21-41[180_29]
5-16	421-428	failure	event[29]	new[29]	_	_
5-17	429-430	,	_	_	_	_
5-18	431-434	and	_	_	_	_
5-19	435-441	stroke	abstract	new	coref	5-21[32_0]
5-20	442-446	were	_	_	_	_
5-21	447-458	independent	abstract[32]	giv[32]	_	_
5-22	459-463	risk	abstract|abstract[32]	new|giv[32]	coref	25-13[209_0]
5-23	464-471	factors	abstract[32]	giv[32]	_	_
5-24	472-474	of	abstract[32]	giv[32]	_	_
5-25	475-484	mortality	abstract[32]|event	giv[32]|new	coref	25-17[210_0]
5-26	485-488	for	abstract[32]	giv[32]	_	_
5-27	489-493	both	abstract[32]|abstract[34]	giv[32]|giv[34]	coref	10-5[0_34]
5-28	494-497	NIE	abstract[32]|abstract[34]	giv[32]|giv[34]	_	_
5-29	498-501	and	abstract[32]	giv[32]	_	_
5-30	502-505	CIE	abstract[32]|abstract	giv[32]|giv	coref	6-21
5-31	506-507	.	_	_	_	_

#Text=In addition , the female sex , renal disease , and use of pacemakers or defibrillators were mortality-associated factors of CIE .
6-1	508-510	In	_	_	_	_
6-2	511-519	addition	_	_	_	_
6-3	520-521	,	_	_	_	_
6-4	522-525	the	abstract[36]	new[36]	_	_
6-5	526-532	female	abstract[36]	new[36]	_	_
6-6	533-536	sex	abstract[36]	new[36]	_	_
6-7	537-538	,	_	_	_	_
6-8	539-544	renal	abstract[37]	new[37]	coref	16-16[118_37]
6-9	545-552	disease	abstract[37]	new[37]	_	_
6-10	553-554	,	_	_	_	_
6-11	555-558	and	_	_	_	_
6-12	559-562	use	abstract[38]	new[38]	coref	6-18[41_38]
6-13	563-565	of	abstract[38]	new[38]	_	_
6-14	566-576	pacemakers	abstract[38]|object	new[38]|new	_	_
6-15	577-579	or	abstract[38]	new[38]	_	_
6-16	580-594	defibrillators	abstract[38]|object	new[38]|new	_	_
6-17	595-599	were	_	_	_	_
6-18	600-620	mortality-associated	abstract[41]	giv[41]	coref	21-2[164_41]
6-19	621-628	factors	abstract[41]	giv[41]	_	_
6-20	629-631	of	abstract[41]	giv[41]	_	_
6-21	632-635	CIE	abstract[41]|abstract	giv[41]|giv	_	_
6-22	636-637	.	_	_	_	_

#Text=Numerous studies have confirmed a rising trend of IE rates over time .
7-1	638-646	Numerous	abstract[43]	new[43]	coref	17-24[130_43]
7-2	647-654	studies	abstract[43]	new[43]	_	_
7-3	655-659	have	_	_	_	_
7-4	660-669	confirmed	_	_	_	_
7-5	670-671	a	abstract[44]	new[44]	coref	14-1[96_44]
7-6	672-678	rising	abstract[44]	new[44]	_	_
7-7	679-684	trend	abstract[44]	new[44]	_	_
7-8	685-687	of	abstract[44]	new[44]	_	_
7-9	688-690	IE	abstract[44]|object|abstract[46]	new[44]|giv|new[46]	coref|coref	8-12[50_0]|22-32[192_46]
7-10	691-696	rates	abstract[44]|abstract[46]	new[44]|new[46]	_	_
7-11	697-701	over	_	_	_	_
7-12	702-706	time	_	_	_	_
7-13	707-708	.	_	_	_	_

#Text=Olmos et al. found a significant increase in the incidence of IE in Spain from 2003 to 2014 .
8-1	709-714	Olmos	person	new	_	_
8-2	715-717	et	_	_	_	_
8-3	718-721	al.	_	_	_	_
8-4	722-727	found	_	_	_	_
8-5	728-729	a	abstract[48]	giv[48]	coref	10-10[65_48]
8-6	730-741	significant	abstract[48]	giv[48]	_	_
8-7	742-750	increase	abstract[48]	giv[48]	_	_
8-8	751-753	in	abstract[48]	giv[48]	_	_
8-9	754-757	the	abstract[48]|abstract[49]	giv[48]|new[49]	_	_
8-10	758-767	incidence	abstract[48]|abstract[49]	giv[48]|new[49]	_	_
8-11	768-770	of	abstract[48]|abstract[49]	giv[48]|new[49]	_	_
8-12	771-773	IE	abstract[48]|abstract[49]|object[50]	giv[48]|new[49]|giv[50]	coref	9-11[0_50]
8-13	774-776	in	abstract[48]|abstract[49]|object[50]	giv[48]|new[49]|giv[50]	_	_
8-14	777-782	Spain	abstract[48]|abstract[49]|object[50]|place	giv[48]|new[49]|giv[50]|giv	coref	27-1[218_0]
8-15	783-787	from	_	_	_	_
8-16	788-792	2003	time	new	_	_
8-17	793-795	to	_	_	_	_
8-18	796-800	2014	time	new	_	_
8-19	801-802	.	_	_	_	_

#Text=Similarly , Bor et al. reported the rising number of IE episodes is due to Staphylococcus aureus infections associated with cardiac devices and implants .
9-1	803-812	Similarly	_	_	_	_
9-2	813-814	,	_	_	_	_
9-3	815-818	Bor	person	new	_	_
9-4	819-821	et	_	_	_	_
9-5	822-825	al.	_	_	_	_
9-6	826-834	reported	_	_	_	_
9-7	835-838	the	abstract[55]	new[55]	_	_
9-8	839-845	rising	abstract[55]	new[55]	_	_
9-9	846-852	number	abstract[55]	new[55]	_	_
9-10	853-855	of	abstract[55]	new[55]	_	_
9-11	856-858	IE	abstract[55]|object|event[57]	new[55]|giv|new[57]	coref|coref	11-7|15-28[112_57]
9-12	859-867	episodes	abstract[55]|event[57]	new[55]|new[57]	_	_
9-13	868-870	is	_	_	_	_
9-14	871-874	due	_	_	_	_
9-15	875-877	to	_	_	_	_
9-16	878-892	Staphylococcus	object|event[60]	new|new[60]	coref|coref	20-41[159_60]|25-5
9-17	893-899	aureus	object|event[60]	new|new[60]	coref	25-5[207_0]
9-18	900-910	infections	event[60]	new[60]	_	_
9-19	911-921	associated	event[60]	new[60]	_	_
9-20	922-926	with	event[60]	new[60]	_	_
9-21	927-934	cardiac	event[60]|object[61]	new[60]|new[61]	coref	10-33[74_61]
9-22	935-942	devices	event[60]|object[61]	new[60]|new[61]	_	_
9-23	943-946	and	event[60]	new[60]	_	_
9-24	947-955	implants	event[60]|object	new[60]|new	_	_
9-25	956-957	.	_	_	_	_

#Text=The growing incidence of NIE could be related to the increase in the prevalence of healthcare-associated interventional procedures in recent years ( e.g. , hemodialysis , catheterization , intravenous line placement , cardiac implantable electronic devices , prostheses ) .
10-1	958-961	The	abstract[63]	new[63]	_	_
10-2	962-969	growing	abstract[63]	new[63]	_	_
10-3	970-979	incidence	abstract[63]	new[63]	_	_
10-4	980-982	of	abstract[63]	new[63]	_	_
10-5	983-986	NIE	abstract[63]|abstract	new[63]|giv	coref	15-10
10-6	987-992	could	_	_	_	_
10-7	993-995	be	_	_	_	_
10-8	996-1003	related	_	_	_	_
10-9	1004-1006	to	_	_	_	_
10-10	1007-1010	the	abstract[65]	giv[65]	appos	10-23[69_65]
10-11	1011-1019	increase	abstract[65]	giv[65]	_	_
10-12	1020-1022	in	abstract[65]	giv[65]	_	_
10-13	1023-1026	the	abstract[65]|abstract[66]	giv[65]|new[66]	_	_
10-14	1027-1037	prevalence	abstract[65]|abstract[66]	giv[65]|new[66]	_	_
10-15	1038-1040	of	abstract[65]|abstract[66]	giv[65]|new[66]	_	_
10-16	1041-1062	healthcare-associated	abstract[65]|abstract[66]|abstract[67]	giv[65]|new[66]|new[67]	coref	13-24[91_67]
10-17	1063-1077	interventional	abstract[65]|abstract[66]|abstract[67]	giv[65]|new[66]|new[67]	_	_
10-18	1078-1088	procedures	abstract[65]|abstract[66]|abstract[67]	giv[65]|new[66]|new[67]	_	_
10-19	1089-1091	in	abstract[65]	giv[65]	_	_
10-20	1092-1098	recent	abstract[65]|time[68]	giv[65]|new[68]	coref	11-14[79_68]
10-21	1099-1104	years	abstract[65]|time[68]	giv[65]|new[68]	_	_
10-22	1105-1106	(	_	_	_	_
10-23	1107-1111	e.g.	abstract[69]|abstract[70]	giv[69]|giv[70]	appos|appos	10-23[70_69]|10-27[0_70]
10-24	1112-1113	,	abstract[69]|abstract[70]	giv[69]|giv[70]	_	_
10-25	1114-1126	hemodialysis	abstract[69]|abstract[70]	giv[69]|giv[70]	_	_
10-26	1127-1128	,	abstract[70]	giv[70]	_	_
10-27	1129-1144	catheterization	abstract[70]|abstract	giv[70]|giv	appos	10-29[73_0]
10-28	1145-1146	,	abstract[70]	giv[70]	_	_
10-29	1147-1158	intravenous	abstract[70]|object[72]|abstract[73]	giv[70]|new[72]|giv[73]	ana	11-3[0_73]
10-30	1159-1163	line	abstract[70]|object[72]|abstract[73]	giv[70]|new[72]|giv[73]	_	_
10-31	1164-1173	placement	abstract[70]|abstract[73]	giv[70]|giv[73]	_	_
10-32	1174-1175	,	abstract[70]	giv[70]	_	_
10-33	1176-1183	cardiac	abstract[70]|object[74]	giv[70]|giv[74]	_	_
10-34	1184-1195	implantable	abstract[70]|object[74]	giv[70]|giv[74]	_	_
10-35	1196-1206	electronic	abstract[70]|object[74]	giv[70]|giv[74]	_	_
10-36	1207-1214	devices	abstract[70]|object[74]	giv[70]|giv[74]	_	_
10-37	1215-1216	,	abstract[70]	giv[70]	_	_
10-38	1217-1227	prostheses	abstract[70]|object	giv[70]|new	_	_
10-39	1228-1229	)	_	_	_	_
10-40	1230-1231	.	_	_	_	_

#Text=Furthermore , this probably explains why IE rose in those patients older than 80 years .
11-1	1232-1243	Furthermore	_	_	_	_
11-2	1244-1245	,	_	_	_	_
11-3	1246-1250	this	abstract	giv	coref	14-11[98_0]
11-4	1251-1259	probably	_	_	_	_
11-5	1260-1268	explains	_	_	_	_
11-6	1269-1272	why	_	_	_	_
11-7	1273-1275	IE	object	giv	coref	12-16
11-8	1276-1280	rose	_	_	_	_
11-9	1281-1283	in	_	_	_	_
11-10	1284-1289	those	person[78]	giv[78]	coref	13-27[92_78]
11-11	1290-1298	patients	person[78]	giv[78]	_	_
11-12	1299-1304	older	person[78]	giv[78]	_	_
11-13	1305-1309	than	_	_	_	_
11-14	1310-1312	80	time[79]	giv[79]	_	_
11-15	1313-1318	years	time[79]	giv[79]	_	_
11-16	1319-1320	.	_	_	_	_

#Text=Another factor explaining the consistently increasing pattern might be the changes in the prevention of IE .
12-1	1321-1328	Another	abstract[80]	new[80]	coref	12-10[82_80]
12-2	1329-1335	factor	abstract[80]	new[80]	_	_
12-3	1336-1346	explaining	abstract[80]	new[80]	_	_
12-4	1347-1350	the	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-5	1351-1363	consistently	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-6	1364-1374	increasing	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-7	1375-1382	pattern	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-8	1383-1388	might	_	_	_	_
12-9	1389-1391	be	_	_	_	_
12-10	1392-1395	the	abstract[82]	giv[82]	coref	25-8[208_82]
12-11	1396-1403	changes	abstract[82]	giv[82]	_	_
12-12	1404-1406	in	abstract[82]	giv[82]	_	_
12-13	1407-1410	the	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-14	1411-1421	prevention	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-15	1422-1424	of	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
12-16	1425-1427	IE	abstract[82]|abstract[83]|object	giv[82]|new[83]|giv	coref	14-15
12-17	1428-1429	.	_	_	_	_

#Text=The American Heart Association in 2007 revised and changed the consensus for antibiotic prophylaxis , recommending the withdrawal of routine antibiotic prophylaxis for dental procedures in low-risk and moderate-risk patients and most other invasive procedures in all patients .
13-1	1430-1433	The	organization[85]	new[85]	_	_
13-2	1434-1442	American	organization[85]	new[85]	_	_
13-3	1443-1448	Heart	organization[85]	new[85]	_	_
13-4	1449-1460	Association	organization[85]	new[85]	_	_
13-5	1461-1463	in	organization[85]	new[85]	_	_
13-6	1464-1468	2007	organization[85]|time	new[85]|new	_	_
13-7	1469-1476	revised	_	_	_	_
13-8	1477-1480	and	_	_	_	_
13-9	1481-1488	changed	_	_	_	_
13-10	1489-1492	the	abstract[87]	new[87]	coref	20-53[0_87]
13-11	1493-1502	consensus	abstract[87]	new[87]	_	_
13-12	1503-1506	for	abstract[87]	new[87]	_	_
13-13	1507-1517	antibiotic	abstract[87]|abstract[88]	new[87]|new[88]	coref	13-20[90_88]
13-14	1518-1529	prophylaxis	abstract[87]|abstract[88]	new[87]|new[88]	_	_
13-15	1530-1531	,	_	_	_	_
13-16	1532-1544	recommending	_	_	_	_
13-17	1545-1548	the	event[89]	new[89]	_	_
13-18	1549-1559	withdrawal	event[89]	new[89]	_	_
13-19	1560-1562	of	event[89]	new[89]	_	_
13-20	1563-1570	routine	event[89]|abstract[90]	new[89]|giv[90]	_	_
13-21	1571-1581	antibiotic	event[89]|abstract[90]	new[89]|giv[90]	_	_
13-22	1582-1593	prophylaxis	event[89]|abstract[90]	new[89]|giv[90]	_	_
13-23	1594-1597	for	event[89]|abstract[90]	new[89]|giv[90]	_	_
13-24	1598-1604	dental	event[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	coref	13-32[94_91]
13-25	1605-1615	procedures	event[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
13-26	1616-1618	in	event[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
13-27	1619-1627	low-risk	event[89]|abstract[90]|abstract[91]|person[92]|person[93]	new[89]|giv[90]|giv[91]|giv[92]|giv[93]	coref|coref	13-27[93_92]|13-37[95_93]
13-28	1628-1631	and	event[89]|abstract[90]|abstract[91]|person[92]|person[93]	new[89]|giv[90]|giv[91]|giv[92]|giv[93]	_	_
13-29	1632-1645	moderate-risk	event[89]|abstract[90]|abstract[91]|person[92]|person[93]	new[89]|giv[90]|giv[91]|giv[92]|giv[93]	_	_
13-30	1646-1654	patients	event[89]|abstract[90]|abstract[91]|person[92]|person[93]	new[89]|giv[90]|giv[91]|giv[92]|giv[93]	_	_
13-31	1655-1658	and	event[89]|abstract[90]|abstract[91]|person[93]	new[89]|giv[90]|giv[91]|giv[93]	_	_
13-32	1659-1663	most	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]	coref	16-10[115_94]
13-33	1664-1669	other	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]	_	_
13-34	1670-1678	invasive	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]	_	_
13-35	1679-1689	procedures	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]	_	_
13-36	1690-1692	in	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]	_	_
13-37	1693-1696	all	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]|person[95]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]|giv[95]	coref	16-20[119_95]
13-38	1697-1705	patients	event[89]|abstract[90]|abstract[91]|person[93]|abstract[94]|person[95]	new[89]|giv[90]|giv[91]|giv[93]|giv[94]|giv[95]	_	_
13-39	1706-1707	.	_	_	_	_

#Text=A similar trend occurred in the United Kingdom , where a substantial increase in IE cases was reported after the introduction of these guidelines in 2008 .
14-1	1708-1709	A	abstract[96]	giv[96]	coref	19-7[141_96]
14-2	1710-1717	similar	abstract[96]	giv[96]	_	_
14-3	1718-1723	trend	abstract[96]	giv[96]	_	_
14-4	1724-1732	occurred	_	_	_	_
14-5	1733-1735	in	_	_	_	_
14-6	1736-1739	the	place[97]	new[97]	_	_
14-7	1740-1746	United	place[97]	new[97]	_	_
14-8	1747-1754	Kingdom	place[97]	new[97]	_	_
14-9	1755-1756	,	place[97]	new[97]	_	_
14-10	1757-1762	where	place[97]	new[97]	_	_
14-11	1763-1764	a	place[97]|abstract[98]	new[97]|giv[98]	coref	21-18[0_98]
14-12	1765-1776	substantial	place[97]|abstract[98]	new[97]|giv[98]	_	_
14-13	1777-1785	increase	place[97]|abstract[98]	new[97]|giv[98]	_	_
14-14	1786-1788	in	place[97]|abstract[98]	new[97]|giv[98]	_	_
14-15	1789-1791	IE	place[97]|abstract[98]|object|abstract[100]	new[97]|giv[98]|giv|new[100]	coref|coref	15-6[106_0]|20-13[151_100]
14-16	1792-1797	cases	place[97]|abstract[98]|abstract[100]	new[97]|giv[98]|new[100]	_	_
14-17	1798-1801	was	place[97]	new[97]	_	_
14-18	1802-1810	reported	place[97]	new[97]	_	_
14-19	1811-1816	after	place[97]	new[97]	_	_
14-20	1817-1820	the	place[97]|event[101]	new[97]|new[101]	_	_
14-21	1821-1833	introduction	place[97]|event[101]	new[97]|new[101]	_	_
14-22	1834-1836	of	place[97]|event[101]	new[97]|new[101]	_	_
14-23	1837-1842	these	place[97]|event[101]|abstract[102]	new[97]|new[101]|new[102]	_	_
14-24	1843-1853	guidelines	place[97]|event[101]|abstract[102]	new[97]|new[101]|new[102]	_	_
14-25	1854-1856	in	place[97]	new[97]	_	_
14-26	1857-1861	2008	place[97]|time	new[97]|new	coref	18-18[139_0]
14-27	1862-1863	.	_	_	_	_

#Text=We identified 45.9 % of all IE to be NIE , which is moderately higher than previous reports , accounting for 10 % to 30 % of all IE episodes .
15-1	1864-1866	We	person	giv	ana	17-2
15-2	1867-1877	identified	_	_	_	_
15-3	1878-1882	45.9	abstract[105]	new[105]	_	_
15-4	1883-1884	%	abstract[105]	new[105]	_	_
15-5	1885-1887	of	abstract[105]	new[105]	_	_
15-6	1888-1891	all	abstract[105]|object[106]	new[105]|giv[106]	coref	15-29[0_106]
15-7	1892-1894	IE	abstract[105]|object[106]	new[105]|giv[106]	_	_
15-8	1895-1897	to	abstract[105]	new[105]	_	_
15-9	1898-1900	be	abstract[105]	new[105]	_	_
15-10	1901-1904	NIE	abstract[105]|abstract	new[105]|giv	coref	20-26[156_0]
15-11	1905-1906	,	abstract[105]	new[105]	_	_
15-12	1907-1912	which	abstract[105]	new[105]	_	_
15-13	1913-1915	is	abstract[105]	new[105]	_	_
15-14	1916-1926	moderately	abstract[105]	new[105]	_	_
15-15	1927-1933	higher	abstract[105]	new[105]	_	_
15-16	1934-1938	than	abstract[105]	new[105]	_	_
15-17	1939-1947	previous	abstract[105]|abstract[108]	new[105]|new[108]	_	_
15-18	1948-1955	reports	abstract[105]|abstract[108]	new[105]|new[108]	_	_
15-19	1956-1957	,	_	_	_	_
15-20	1958-1968	accounting	_	_	_	_
15-21	1969-1972	for	_	_	_	_
15-22	1973-1975	10	abstract[109]	new[109]	_	_
15-23	1976-1977	%	abstract[109]	new[109]	_	_
15-24	1978-1980	to	abstract[109]	new[109]	_	_
15-25	1981-1983	30	abstract[109]	new[109]	_	_
15-26	1984-1985	%	abstract[110]	new[110]	_	_
15-27	1986-1988	of	abstract[110]	new[110]	_	_
15-28	1989-1992	all	abstract[110]|event[112]	new[110]|giv[112]	_	_
15-29	1993-1995	IE	abstract[110]|object|event[112]	new[110]|giv|giv[112]	coref	19-22
15-30	1996-2004	episodes	abstract[110]|event[112]	new[110]|giv[112]	_	_
15-31	2005-2006	.	_	_	_	_

#Text=This finding might be related to the increment of invasive procedures , major incidence of degenerative valve disease in elderly patients , and longer intensive care unit and hospital stays .
16-1	2007-2011	This	abstract[113]	new[113]	_	_
16-2	2012-2019	finding	abstract[113]	new[113]	_	_
16-3	2020-2025	might	_	_	_	_
16-4	2026-2028	be	_	_	_	_
16-5	2029-2036	related	_	_	_	_
16-6	2037-2039	to	_	_	_	_
16-7	2040-2043	the	event[114]	new[114]	_	_
16-8	2044-2053	increment	event[114]	new[114]	_	_
16-9	2054-2056	of	event[114]	new[114]	_	_
16-10	2057-2065	invasive	event[114]|abstract[115]	new[114]|giv[115]	_	_
16-11	2066-2076	procedures	event[114]|abstract[115]	new[114]|giv[115]	_	_
16-12	2077-2078	,	_	_	_	_
16-13	2079-2084	major	abstract[116]	new[116]	_	_
16-14	2085-2094	incidence	abstract[116]	new[116]	_	_
16-15	2095-2097	of	abstract[116]	new[116]	_	_
16-16	2098-2110	degenerative	abstract[116]|abstract[118]	new[116]|giv[118]	coref	21-20[172_118]
16-17	2111-2116	valve	abstract[116]|object|abstract[118]	new[116]|new|giv[118]	_	_
16-18	2117-2124	disease	abstract[116]|abstract[118]	new[116]|giv[118]	_	_
16-19	2125-2127	in	abstract[116]|abstract[118]	new[116]|giv[118]	_	_
16-20	2128-2135	elderly	abstract[116]|abstract[118]|person[119]	new[116]|giv[118]|giv[119]	coref	17-8[0_119]
16-21	2136-2144	patients	abstract[116]|abstract[118]|person[119]	new[116]|giv[118]|giv[119]	_	_
16-22	2145-2146	,	_	_	_	_
16-23	2147-2150	and	_	_	_	_
16-24	2151-2157	longer	place[121]|event[123]	new[121]|new[123]	_	_
16-25	2158-2167	intensive	abstract[120]|place[121]|event[123]	new[120]|new[121]|new[123]	_	_
16-26	2168-2172	care	abstract[120]|place[121]|event[123]	new[120]|new[121]|new[123]	_	_
16-27	2173-2177	unit	place[121]|event[123]	new[121]|new[123]	_	_
16-28	2178-2181	and	event[123]	new[123]	_	_
16-29	2182-2190	hospital	place|event[123]	new|new[123]	_	_
16-30	2191-2196	stays	event[123]	new[123]	_	_
16-31	2197-2198	.	_	_	_	_

#Text=In our study , 24.5 % of patients underwent cardiac surgery during admission , which is similar to what has been reported in population-based studies from Italy and the United States .
17-1	2199-2201	In	_	_	_	_
17-2	2202-2205	our	person|abstract[125]	giv|new[125]	coref|ana	18-19[0_125]|20-19
17-3	2206-2211	study	abstract[125]	new[125]	_	_
17-4	2212-2213	,	_	_	_	_
17-5	2214-2218	24.5	person[126]	new[126]	_	_
17-6	2219-2220	%	person[126]	new[126]	_	_
17-7	2221-2223	of	person[126]	new[126]	_	_
17-8	2224-2232	patients	person[126]|person	new[126]|giv	coref	19-20[145_0]
17-9	2233-2242	underwent	_	_	_	_
17-10	2243-2250	cardiac	event[128]	new[128]	_	_
17-11	2251-2258	surgery	event[128]	new[128]	_	_
17-12	2259-2265	during	_	_	_	_
17-13	2266-2275	admission	event	new	_	_
17-14	2276-2277	,	_	_	_	_
17-15	2278-2283	which	_	_	_	_
17-16	2284-2286	is	_	_	_	_
17-17	2287-2294	similar	_	_	_	_
17-18	2295-2297	to	_	_	_	_
17-19	2298-2302	what	_	_	_	_
17-20	2303-2306	has	_	_	_	_
17-21	2307-2311	been	_	_	_	_
17-22	2312-2320	reported	_	_	_	_
17-23	2321-2323	in	_	_	_	_
17-24	2324-2340	population-based	abstract[130]	giv[130]	_	_
17-25	2341-2348	studies	abstract[130]	giv[130]	_	_
17-26	2349-2353	from	abstract[130]	giv[130]	_	_
17-27	2354-2359	Italy	abstract[130]|place	giv[130]|new	_	_
17-28	2360-2363	and	abstract[130]	giv[130]	_	_
17-29	2364-2367	the	abstract[130]|place[132]	giv[130]|new[132]	coref	19-15[144_132]
17-30	2368-2374	United	abstract[130]|place[132]	giv[130]|new[132]	_	_
17-31	2375-2381	States	abstract[130]|place[132]	giv[130]|new[132]	_	_
17-32	2382-2383	.	_	_	_	_

#Text=In terms of gender , a major predominance of men was observed in comparison with women throughout the study period .
18-1	2384-2386	In	_	_	_	_
18-2	2387-2392	terms	_	_	_	_
18-3	2393-2395	of	_	_	_	_
18-4	2396-2402	gender	abstract	new	_	_
18-5	2403-2404	,	_	_	_	_
18-6	2405-2406	a	abstract[134]	new[134]	_	_
18-7	2407-2412	major	abstract[134]	new[134]	_	_
18-8	2413-2425	predominance	abstract[134]	new[134]	_	_
18-9	2426-2428	of	abstract[134]	new[134]	_	_
18-10	2429-2432	men	abstract[134]|person	new[134]|new	_	_
18-11	2433-2436	was	_	_	_	_
18-12	2437-2445	observed	_	_	_	_
18-13	2446-2448	in	_	_	_	_
18-14	2449-2459	comparison	abstract[136]	new[136]	_	_
18-15	2460-2464	with	abstract[136]	new[136]	_	_
18-16	2465-2470	women	abstract[136]|person	new[136]|new	ana	19-11
18-17	2471-2481	throughout	_	_	_	_
18-18	2482-2485	the	time[139]	giv[139]	coref	19-30[148_139]
18-19	2486-2491	study	abstract|time[139]	giv|giv[139]	coref	19-31
18-20	2492-2498	period	time[139]	giv[139]	_	_
18-21	2499-2500	.	_	_	_	_

#Text=Likewise , Toyoda et al. found a similar trend in their investigation conducted in the United States in which patients with IE were more likely to be male throughout the study period .
19-1	2501-2509	Likewise	_	_	_	_
19-2	2510-2511	,	_	_	_	_
19-3	2512-2518	Toyoda	person	new	coref	20-4
19-4	2519-2521	et	_	_	_	_
19-5	2522-2525	al.	_	_	_	_
19-6	2526-2531	found	_	_	_	_
19-7	2532-2533	a	abstract[141]	giv[141]	_	_
19-8	2534-2541	similar	abstract[141]	giv[141]	_	_
19-9	2542-2547	trend	abstract[141]	giv[141]	_	_
19-10	2548-2550	in	_	_	_	_
19-11	2551-2556	their	person|abstract[143]	giv|new[143]	_	_
19-12	2557-2570	investigation	abstract[143]	new[143]	_	_
19-13	2571-2580	conducted	abstract[143]	new[143]	_	_
19-14	2581-2583	in	abstract[143]	new[143]	_	_
19-15	2584-2587	the	abstract[143]|place[144]	new[143]|giv[144]	_	_
19-16	2588-2594	United	abstract[143]|place[144]	new[143]|giv[144]	_	_
19-17	2595-2601	States	abstract[143]|place[144]	new[143]|giv[144]	_	_
19-18	2602-2604	in	abstract[143]	new[143]	_	_
19-19	2605-2610	which	abstract[143]	new[143]	_	_
19-20	2611-2619	patients	abstract[143]|person[145]	new[143]|giv[145]	coref	21-51[182_145]
19-21	2620-2624	with	abstract[143]|person[145]	new[143]|giv[145]	_	_
19-22	2625-2627	IE	abstract[143]|person[145]|object	new[143]|giv[145]|giv	coref	23-16
19-23	2628-2632	were	abstract[143]	new[143]	_	_
19-24	2633-2637	more	abstract[143]	new[143]	_	_
19-25	2638-2644	likely	abstract[143]	new[143]	_	_
19-26	2645-2647	to	abstract[143]	new[143]	_	_
19-27	2648-2650	be	abstract[143]	new[143]	_	_
19-28	2651-2655	male	abstract[143]	new[143]	_	_
19-29	2656-2666	throughout	_	_	_	_
19-30	2667-2670	the	time[148]	giv[148]	_	_
19-31	2671-2676	study	abstract|time[148]	giv|giv[148]	_	_
19-32	2677-2683	period	time[148]	giv[148]	_	_
19-33	2684-2685	.	_	_	_	_

#Text=In contrast with Toyoda et al. , who described a decline in the cases of nosocomial endocarditis , our findings highlight the paramount importance of NIE , the incidence of which steeply rose despite all the coordinated efforts to reduce hospital-acquired infections through mandatory continuous reporting , regulated interventions , or evidence-based consensus recommendations .
20-1	2686-2688	In	_	_	_	_
20-2	2689-2697	contrast	_	_	_	_
20-3	2698-2702	with	_	_	_	_
20-4	2703-2709	Toyoda	person	giv	coref	26-23
20-5	2710-2712	et	_	_	_	_
20-6	2713-2716	al.	_	_	_	_
20-7	2717-2718	,	_	_	_	_
20-8	2719-2722	who	_	_	_	_
20-9	2723-2732	described	_	_	_	_
20-10	2733-2734	a	event[150]	giv[150]	_	_
20-11	2735-2742	decline	event[150]	giv[150]	_	_
20-12	2743-2745	in	event[150]	giv[150]	_	_
20-13	2746-2749	the	event[150]|abstract[151]	giv[150]|giv[151]	_	_
20-14	2750-2755	cases	event[150]|abstract[151]	giv[150]|giv[151]	_	_
20-15	2756-2758	of	event[150]|abstract[151]	giv[150]|giv[151]	_	_
20-16	2759-2769	nosocomial	event[150]|abstract[151]|abstract[152]	giv[150]|giv[151]|new[152]	_	_
20-17	2770-2782	endocarditis	event[150]|abstract[151]|abstract[152]	giv[150]|giv[151]|new[152]	_	_
20-18	2783-2784	,	_	_	_	_
20-19	2785-2788	our	person|abstract[154]	giv|new[154]	coref|ana	26-23[217_154]|30-4
20-20	2789-2797	findings	abstract[154]	new[154]	_	_
20-21	2798-2807	highlight	_	_	_	_
20-22	2808-2811	the	abstract[155]	new[155]	_	_
20-23	2812-2821	paramount	abstract[155]	new[155]	_	_
20-24	2822-2832	importance	abstract[155]	new[155]	_	_
20-25	2833-2835	of	abstract[155]	new[155]	_	_
20-26	2836-2839	NIE	abstract[155]|abstract[156]	new[155]|giv[156]	coref	21-53[0_156]
20-27	2840-2841	,	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
20-28	2842-2845	the	abstract[155]|abstract[156]|abstract[157]	new[155]|giv[156]|new[157]	coref	28-1[238_157]
20-29	2846-2855	incidence	abstract[155]|abstract[156]|abstract[157]	new[155]|giv[156]|new[157]	_	_
20-30	2856-2858	of	abstract[155]|abstract[156]|abstract[157]	new[155]|giv[156]|new[157]	_	_
20-31	2859-2864	which	abstract[155]|abstract[156]|abstract[157]	new[155]|giv[156]|new[157]	_	_
20-32	2865-2872	steeply	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
20-33	2873-2877	rose	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
20-34	2878-2885	despite	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
20-35	2886-2889	all	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-36	2890-2893	the	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-37	2894-2905	coordinated	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-38	2906-2913	efforts	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-39	2914-2916	to	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-40	2917-2923	reduce	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-41	2924-2941	hospital-acquired	abstract[155]|abstract[156]|abstract[158]|event[159]	new[155]|giv[156]|new[158]|giv[159]	coref	32-3[268_159]
20-42	2942-2952	infections	abstract[155]|abstract[156]|abstract[158]|event[159]	new[155]|giv[156]|new[158]|giv[159]	_	_
20-43	2953-2960	through	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-44	2961-2970	mandatory	abstract[155]|abstract[156]|abstract[158]|event[160]	new[155]|giv[156]|new[158]|new[160]	_	_
20-45	2971-2981	continuous	abstract[155]|abstract[156]|abstract[158]|event[160]	new[155]|giv[156]|new[158]|new[160]	_	_
20-46	2982-2991	reporting	abstract[155]|abstract[156]|abstract[158]|event[160]	new[155]|giv[156]|new[158]|new[160]	_	_
20-47	2992-2993	,	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-48	2994-3003	regulated	abstract[155]|abstract[156]|abstract[158]|event[161]	new[155]|giv[156]|new[158]|new[161]	_	_
20-49	3004-3017	interventions	abstract[155]|abstract[156]|abstract[158]|event[161]	new[155]|giv[156]|new[158]|new[161]	_	_
20-50	3018-3019	,	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-51	3020-3022	or	abstract[155]|abstract[156]|abstract[158]	new[155]|giv[156]|new[158]	_	_
20-52	3023-3037	evidence-based	abstract[155]|abstract[156]|abstract[158]|abstract[163]	new[155]|giv[156]|new[158]|new[163]	_	_
20-53	3038-3047	consensus	abstract[155]|abstract[156]|abstract[158]|abstract|abstract[163]	new[155]|giv[156]|new[158]|giv|new[163]	_	_
20-54	3048-3063	recommendations	abstract[155]|abstract[156]|abstract[158]|abstract[163]	new[155]|giv[156]|new[158]|new[163]	_	_
20-55	3064-3065	.	_	_	_	_

#Text=Concerning predisposing factors , a higher Charlson index ( reflecting more comorbidities such as diabetes mellitus , hemodialysis , coronary artery disease , peripheral artery disease , cancer , as well as major complications ranging from sepsis , shock , heart failure , and cerebrovascular disease ) were present in patients with NIE .
21-1	3066-3076	Concerning	_	_	_	_
21-2	3077-3089	predisposing	abstract[164]	giv[164]	_	_
21-3	3090-3097	factors	abstract[164]	giv[164]	_	_
21-4	3098-3099	,	_	_	_	_
21-5	3100-3101	a	abstract[166]	giv[166]	_	_
21-6	3102-3108	higher	abstract[166]	giv[166]	_	_
21-7	3109-3117	Charlson	person|abstract[166]	giv|giv[166]	_	_
21-8	3118-3123	index	abstract[166]	giv[166]	_	_
21-9	3124-3125	(	abstract[166]	giv[166]	_	_
21-10	3126-3136	reflecting	abstract[166]	giv[166]	_	_
21-11	3137-3141	more	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-12	3142-3155	comorbidities	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-13	3156-3160	such	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-14	3161-3163	as	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-15	3164-3172	diabetes	abstract[166]|abstract[167]|abstract|abstract[169]	giv[166]|new[167]|new|new[169]	_	_
21-16	3173-3181	mellitus	abstract[166]|abstract[167]|abstract[169]	giv[166]|new[167]|new[169]	_	_
21-17	3182-3183	,	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-18	3184-3196	hemodialysis	abstract[166]|abstract[167]|abstract	giv[166]|new[167]|giv	_	_
21-19	3197-3198	,	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-20	3199-3207	coronary	abstract[166]|abstract[167]|abstract[172]	giv[166]|new[167]|giv[172]	coref	21-24[174_172]
21-21	3208-3214	artery	abstract[166]|abstract[167]|object|abstract[172]	giv[166]|new[167]|new|giv[172]	coref	21-24[173_0]
21-22	3215-3222	disease	abstract[166]|abstract[167]|abstract[172]	giv[166]|new[167]|giv[172]	_	_
21-23	3223-3224	,	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-24	3225-3235	peripheral	abstract[166]|abstract[167]|object[173]|abstract[174]	giv[166]|new[167]|giv[173]|giv[174]	coref	21-45[181_174]
21-25	3236-3242	artery	abstract[166]|abstract[167]|object[173]|abstract[174]	giv[166]|new[167]|giv[173]|giv[174]	_	_
21-26	3243-3250	disease	abstract[166]|abstract[167]|abstract[174]	giv[166]|new[167]|giv[174]	_	_
21-27	3251-3252	,	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-28	3253-3259	cancer	abstract[166]|abstract[167]|abstract	giv[166]|new[167]|new	_	_
21-29	3260-3261	,	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-30	3262-3264	as	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-31	3265-3269	well	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-32	3270-3272	as	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
21-33	3273-3278	major	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	coref	24-24[0_176]
21-34	3279-3292	complications	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-35	3293-3300	ranging	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-36	3301-3305	from	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-37	3306-3312	sepsis	abstract[166]|abstract[167]|abstract[176]|abstract	giv[166]|new[167]|new[176]|new	_	_
21-38	3313-3314	,	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-39	3315-3320	shock	abstract[166]|abstract[167]|abstract[176]|event	giv[166]|new[167]|new[176]|giv	_	_
21-40	3321-3322	,	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-41	3323-3328	heart	abstract[166]|abstract[167]|abstract[176]|object|event[180]	giv[166]|new[167]|new[176]|giv|giv[180]	_	_
21-42	3329-3336	failure	abstract[166]|abstract[167]|abstract[176]|event[180]	giv[166]|new[167]|new[176]|giv[180]	_	_
21-43	3337-3338	,	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-44	3339-3342	and	abstract[166]|abstract[167]|abstract[176]	giv[166]|new[167]|new[176]	_	_
21-45	3343-3358	cerebrovascular	abstract[166]|abstract[167]|abstract[176]|abstract[181]	giv[166]|new[167]|new[176]|giv[181]	_	_
21-46	3359-3366	disease	abstract[166]|abstract[167]|abstract[176]|abstract[181]	giv[166]|new[167]|new[176]|giv[181]	_	_
21-47	3367-3368	)	abstract[166]	giv[166]	_	_
21-48	3369-3373	were	_	_	_	_
21-49	3374-3381	present	_	_	_	_
21-50	3382-3384	in	_	_	_	_
21-51	3385-3393	patients	person[182]	giv[182]	_	_
21-52	3394-3398	with	person[182]	giv[182]	_	_
21-53	3399-3402	NIE	person[182]|abstract	giv[182]|giv	coref	22-21
21-54	3403-3404	.	_	_	_	_

#Text=This rise in underlying diseases might be related to the aging of the population and explains why those adults with NIE , especially those older than age 80 years , depicted the lowest survival rates .
22-1	3405-3409	This	event[184]	giv[184]	_	_
22-2	3410-3414	rise	event[184]	giv[184]	_	_
22-3	3415-3417	in	event[184]	giv[184]	_	_
22-4	3418-3428	underlying	event[184]|abstract[185]	giv[184]|new[185]	_	_
22-5	3429-3437	diseases	event[184]|abstract[185]	giv[184]|new[185]	_	_
22-6	3438-3443	might	_	_	_	_
22-7	3444-3446	be	_	_	_	_
22-8	3447-3454	related	_	_	_	_
22-9	3455-3457	to	_	_	_	_
22-10	3458-3461	the	abstract[186]	new[186]	_	_
22-11	3462-3467	aging	abstract[186]	new[186]	_	_
22-12	3468-3470	of	abstract[186]	new[186]	_	_
22-13	3471-3474	the	abstract[186]|person[187]	new[186]|new[187]	_	_
22-14	3475-3485	population	abstract[186]|person[187]	new[186]|new[187]	_	_
22-15	3486-3489	and	_	_	_	_
22-16	3490-3498	explains	_	_	_	_
22-17	3499-3502	why	_	_	_	_
22-18	3503-3508	those	person[188]	new[188]	_	_
22-19	3509-3515	adults	person[188]	new[188]	_	_
22-20	3516-3520	with	person[188]	new[188]	_	_
22-21	3521-3524	NIE	person[188]|abstract	new[188]|giv	_	_
22-22	3525-3526	,	_	_	_	_
22-23	3527-3537	especially	_	_	_	_
22-24	3538-3543	those	_	_	_	_
22-25	3544-3549	older	_	_	_	_
22-26	3550-3554	than	_	_	_	_
22-27	3555-3558	age	abstract[190]	giv[190]	_	_
22-28	3559-3561	80	abstract[190]	giv[190]	_	_
22-29	3562-3567	years	abstract[190]	giv[190]	_	_
22-30	3568-3569	,	_	_	_	_
22-31	3570-3578	depicted	_	_	_	_
22-32	3579-3582	the	abstract[192]	giv[192]	coref	24-21[201_192]
22-33	3583-3589	lowest	abstract[192]	giv[192]	_	_
22-34	3590-3598	survival	event|abstract[192]	new|giv[192]	_	_
22-35	3599-3604	rates	abstract[192]	giv[192]	_	_
22-36	3605-3606	.	_	_	_	_

#Text=Regarding the microbiological profile , Gram-positive pathogens are still the most frequent microorganisms associated with IE , as previously reported in other series .
23-1	3607-3616	Regarding	_	_	_	_
23-2	3617-3620	the	abstract[193]	new[193]	_	_
23-3	3621-3636	microbiological	abstract[193]	new[193]	_	_
23-4	3637-3644	profile	abstract[193]	new[193]	_	_
23-5	3645-3646	,	_	_	_	_
23-6	3647-3660	Gram-positive	animal[194]	new[194]	coref	23-9[195_194]
23-7	3661-3670	pathogens	animal[194]	new[194]	_	_
23-8	3671-3674	are	_	_	_	_
23-9	3675-3680	still	animal[195]	giv[195]	coref	24-1[198_195]
23-10	3681-3684	the	animal[195]	giv[195]	_	_
23-11	3685-3689	most	animal[195]	giv[195]	_	_
23-12	3690-3698	frequent	animal[195]	giv[195]	_	_
23-13	3699-3713	microorganisms	animal[195]	giv[195]	_	_
23-14	3714-3724	associated	animal[195]	giv[195]	_	_
23-15	3725-3729	with	animal[195]	giv[195]	_	_
23-16	3730-3732	IE	animal[195]|object	giv[195]|giv	coref	25-20[211_0]
23-17	3733-3734	,	animal[195]	giv[195]	_	_
23-18	3735-3737	as	animal[195]	giv[195]	_	_
23-19	3738-3748	previously	animal[195]	giv[195]	_	_
23-20	3749-3757	reported	animal[195]	giv[195]	_	_
23-21	3758-3760	in	animal[195]	giv[195]	_	_
23-22	3761-3766	other	animal[195]|abstract[197]	giv[195]|new[197]	_	_
23-23	3767-3773	series	animal[195]|abstract[197]	giv[195]|new[197]	_	_
23-24	3774-3775	.	_	_	_	_

#Text=These microorganisms often have a healthcare-associated origin , widely recognized as virulent and resistant organisms , and are related to high rates of complications and high mortality rates .
24-1	3776-3781	These	animal[198]	giv[198]	coref	26-15[215_198]
24-2	3782-3796	microorganisms	animal[198]	giv[198]	_	_
24-3	3797-3802	often	_	_	_	_
24-4	3803-3807	have	_	_	_	_
24-5	3808-3809	a	abstract[199]	new[199]	_	_
24-6	3810-3831	healthcare-associated	abstract[199]	new[199]	_	_
24-7	3832-3838	origin	abstract[199]	new[199]	_	_
24-8	3839-3840	,	abstract[199]	new[199]	_	_
24-9	3841-3847	widely	abstract[199]	new[199]	_	_
24-10	3848-3858	recognized	abstract[199]	new[199]	_	_
24-11	3859-3861	as	abstract[199]	new[199]	_	_
24-12	3862-3870	virulent	abstract[199]|animal[200]	new[199]|new[200]	_	_
24-13	3871-3874	and	abstract[199]|animal[200]	new[199]|new[200]	_	_
24-14	3875-3884	resistant	abstract[199]|animal[200]	new[199]|new[200]	_	_
24-15	3885-3894	organisms	abstract[199]|animal[200]	new[199]|new[200]	_	_
24-16	3895-3896	,	_	_	_	_
24-17	3897-3900	and	_	_	_	_
24-18	3901-3904	are	_	_	_	_
24-19	3905-3912	related	_	_	_	_
24-20	3913-3915	to	_	_	_	_
24-21	3916-3920	high	abstract[201]|abstract[202]	giv[201]|giv[202]	coref|coref	24-21[202_201]|24-26[204_202]
24-22	3921-3926	rates	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-23	3927-3929	of	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-24	3930-3943	complications	abstract[201]|abstract[202]|abstract	giv[201]|giv[202]|giv	_	_
24-25	3944-3947	and	abstract[202]	giv[202]	_	_
24-26	3948-3952	high	abstract[202]|abstract[204]	giv[202]|giv[204]	coref	30-18[257_204]
24-27	3953-3962	mortality	abstract[202]|abstract[204]	giv[202]|giv[204]	_	_
24-28	3963-3968	rates	abstract[202]|abstract[204]	giv[202]|giv[204]	_	_
24-29	3969-3970	.	_	_	_	_

#Text=Selton-Suty et al. demonstrated Staphylococcus aureus as the only factor associated with a higher risk of in-hospital mortality in healthcare-associated IE .
25-1	3971-3982	Selton-Suty	person	new	_	_
25-2	3983-3985	et	_	_	_	_
25-3	3986-3989	al.	_	_	_	_
25-4	3990-4002	demonstrated	_	_	_	_
25-5	4003-4017	Staphylococcus	object|object[207]	giv|giv[207]	coref|coref	31-20|31-20[264_207]
25-6	4018-4024	aureus	object[207]	giv[207]	_	_
25-7	4025-4027	as	_	_	_	_
25-8	4028-4031	the	abstract[208]	giv[208]	_	_
25-9	4032-4036	only	abstract[208]	giv[208]	_	_
25-10	4037-4043	factor	abstract[208]	giv[208]	_	_
25-11	4044-4054	associated	abstract[208]	giv[208]	_	_
25-12	4055-4059	with	abstract[208]	giv[208]	_	_
25-13	4060-4061	a	abstract[208]|abstract[209]	giv[208]|giv[209]	_	_
25-14	4062-4068	higher	abstract[208]|abstract[209]	giv[208]|giv[209]	_	_
25-15	4069-4073	risk	abstract[208]|abstract[209]	giv[208]|giv[209]	_	_
25-16	4074-4076	of	abstract[208]|abstract[209]	giv[208]|giv[209]	_	_
25-17	4077-4088	in-hospital	abstract[208]|abstract[209]|event[210]	giv[208]|giv[209]|giv[210]	coref	26-11[0_210]
25-18	4089-4098	mortality	abstract[208]|abstract[209]|event[210]	giv[208]|giv[209]|giv[210]	_	_
25-19	4099-4101	in	abstract[208]|abstract[209]|event[210]	giv[208]|giv[209]|giv[210]	_	_
25-20	4102-4123	healthcare-associated	abstract[208]|abstract[209]|event[210]|object[211]	giv[208]|giv[209]|giv[210]|giv[211]	coref	28-3[0_211]
25-21	4124-4126	IE	abstract[208]|abstract[209]|event[210]|object[211]	giv[208]|giv[209]|giv[210]|giv[211]	_	_
25-22	4127-4128	.	_	_	_	_

#Text=Compared with fungi , anaerobic , and streptococcal infection , mortality was higher for Gram-positive and Gram-negative pathogens , which differs from Toyoda et al. ’ s findings .
26-1	4129-4137	Compared	_	_	_	_
26-2	4138-4142	with	_	_	_	_
26-3	4143-4148	fungi	plant|event[213]	new|new[213]	_	_
26-4	4149-4150	,	event[213]	new[213]	_	_
26-5	4151-4160	anaerobic	event[213]	new[213]	_	_
26-6	4161-4162	,	event[213]	new[213]	_	_
26-7	4163-4166	and	event[213]	new[213]	_	_
26-8	4167-4180	streptococcal	event[213]	new[213]	_	_
26-9	4181-4190	infection	event[213]	new[213]	_	_
26-10	4191-4192	,	_	_	_	_
26-11	4193-4202	mortality	event	giv	_	_
26-12	4203-4206	was	_	_	_	_
26-13	4207-4213	higher	_	_	_	_
26-14	4214-4217	for	_	_	_	_
26-15	4218-4231	Gram-positive	animal[215]	giv[215]	_	_
26-16	4232-4235	and	animal[215]	giv[215]	_	_
26-17	4236-4249	Gram-negative	animal[215]	giv[215]	_	_
26-18	4250-4259	pathogens	animal[215]	giv[215]	_	_
26-19	4260-4261	,	animal[215]	giv[215]	_	_
26-20	4262-4267	which	animal[215]	giv[215]	_	_
26-21	4268-4275	differs	animal[215]	giv[215]	_	_
26-22	4276-4280	from	animal[215]	giv[215]	_	_
26-23	4281-4287	Toyoda	animal[215]|person|abstract[217]	giv[215]|giv|giv[217]	coref	29-1[247_217]
26-24	4288-4290	et	animal[215]|abstract[217]	giv[215]|giv[217]	_	_
26-25	4291-4294	al.	animal[215]|abstract[217]	giv[215]|giv[217]	_	_
26-26	4295-4296	’	animal[215]|abstract[217]	giv[215]|giv[217]	_	_
26-27	4297-4298	s	animal[215]|abstract[217]	giv[215]|giv[217]	_	_
26-28	4299-4307	findings	animal[215]|abstract[217]	giv[215]|giv[217]	_	_
26-29	4308-4309	.	_	_	_	_

#Text=Spain ’s climate varies across its geography , resulting in three broad regions : the North , where Atlantic weather characterized by a large proportion of humid days and the prevalence of precipitation ; the Center , distinguished by a continental plateau with less precipitation ; and the South , which is characterized by a Mediterranean climate with almost no precipitation , higher temperatures , and longer , sunny days .
27-1	4310-4315	Spain	place[218]|abstract[219]	giv[218]|new[219]	ana|coref	27-6[0_218]|27-55[233_219]
27-2	4316-4318	’s	place[218]|abstract[219]	giv[218]|new[219]	_	_
27-3	4319-4326	climate	abstract[219]	new[219]	_	_
27-4	4327-4333	varies	_	_	_	_
27-5	4334-4340	across	_	_	_	_
27-6	4341-4344	its	place|abstract[221]	giv|new[221]	coref	28-28
27-7	4345-4354	geography	abstract[221]	new[221]	_	_
27-8	4355-4356	,	_	_	_	_
27-9	4357-4366	resulting	_	_	_	_
27-10	4367-4369	in	_	_	_	_
27-11	4370-4375	three	place[222]	new[222]	coref	28-25[245_222]
27-12	4376-4381	broad	place[222]	new[222]	_	_
27-13	4382-4389	regions	place[222]	new[222]	_	_
27-14	4390-4391	:	_	_	_	_
27-15	4392-4395	the	organization[223]	giv[223]	coref	28-7[0_223]
27-16	4396-4401	North	organization[223]	giv[223]	_	_
27-17	4402-4403	,	organization[223]	giv[223]	_	_
27-18	4404-4409	where	organization[223]	giv[223]	_	_
27-19	4410-4418	Atlantic	organization[223]|abstract[224]	giv[223]|new[224]	coref	32-10[269_224]
27-20	4419-4426	weather	organization[223]|abstract[224]	giv[223]|new[224]	_	_
27-21	4427-4440	characterized	organization[223]	giv[223]	_	_
27-22	4441-4443	by	organization[223]	giv[223]	_	_
27-23	4444-4445	a	organization[223]|abstract[225]	giv[223]|new[225]	_	_
27-24	4446-4451	large	organization[223]|abstract[225]	giv[223]|new[225]	_	_
27-25	4452-4462	proportion	organization[223]|abstract[225]	giv[223]|new[225]	_	_
27-26	4463-4465	of	organization[223]|abstract[225]	giv[223]|new[225]	_	_
27-27	4466-4471	humid	organization[223]|abstract[225]|time[226]	giv[223]|new[225]|new[226]	coref	27-67[236_226]
27-28	4472-4476	days	organization[223]|abstract[225]|time[226]	giv[223]|new[225]|new[226]	_	_
27-29	4477-4480	and	organization[223]	giv[223]	_	_
27-30	4481-4484	the	organization[223]|abstract[227]	giv[223]|new[227]	_	_
27-31	4485-4495	prevalence	organization[223]|abstract[227]	giv[223]|new[227]	_	_
27-32	4496-4498	of	organization[223]|abstract[227]	giv[223]|new[227]	_	_
27-33	4499-4512	precipitation	organization[223]|abstract[227]|substance	giv[223]|new[227]|new	coref	27-44[231_0]
27-34	4513-4514	;	_	_	_	_
27-35	4515-4518	the	place[229]	new[229]	coref	28-22[243_229]
27-36	4519-4525	Center	place[229]	new[229]	_	_
27-37	4526-4527	,	place[229]	new[229]	_	_
27-38	4528-4541	distinguished	place[229]	new[229]	_	_
27-39	4542-4544	by	place[229]	new[229]	_	_
27-40	4545-4546	a	place[229]|place[230]	new[229]|new[230]	_	_
27-41	4547-4558	continental	place[229]|place[230]	new[229]|new[230]	_	_
27-42	4559-4566	plateau	place[229]|place[230]	new[229]|new[230]	_	_
27-43	4567-4571	with	place[229]|place[230]	new[229]|new[230]	_	_
27-44	4572-4576	less	place[229]|place[230]|substance[231]	new[229]|new[230]|giv[231]	coref	27-59[234_231]
27-45	4577-4590	precipitation	place[229]|place[230]|substance[231]	new[229]|new[230]|giv[231]	_	_
27-46	4591-4592	;	_	_	_	_
27-47	4593-4596	and	_	_	_	_
27-48	4597-4600	the	place[232]	new[232]	coref	28-25[0_232]
27-49	4601-4606	South	place[232]	new[232]	_	_
27-50	4607-4608	,	place[232]	new[232]	_	_
27-51	4609-4614	which	place[232]	new[232]	_	_
27-52	4615-4617	is	place[232]	new[232]	_	_
27-53	4618-4631	characterized	place[232]	new[232]	_	_
27-54	4632-4634	by	place[232]	new[232]	_	_
27-55	4635-4636	a	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-56	4637-4650	Mediterranean	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-57	4651-4658	climate	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-58	4659-4663	with	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-59	4664-4670	almost	place[232]|abstract[233]|substance[234]	new[232]|giv[233]|giv[234]	_	_
27-60	4671-4673	no	place[232]|abstract[233]|substance[234]	new[232]|giv[233]|giv[234]	_	_
27-61	4674-4687	precipitation	place[232]|abstract[233]|substance[234]	new[232]|giv[233]|giv[234]	_	_
27-62	4688-4689	,	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-63	4690-4696	higher	place[232]|abstract[233]|abstract[235]	new[232]|giv[233]|new[235]	_	_
27-64	4697-4709	temperatures	place[232]|abstract[233]|abstract[235]	new[232]|giv[233]|new[235]	_	_
27-65	4710-4711	,	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-66	4712-4715	and	place[232]|abstract[233]	new[232]|giv[233]	_	_
27-67	4716-4722	longer	place[232]|abstract[233]|time[236]	new[232]|giv[233]|giv[236]	_	_
27-68	4723-4724	,	place[232]|abstract[233]|time[236]	new[232]|giv[233]|giv[236]	_	_
27-69	4725-4730	sunny	place[232]|abstract[233]|time[236]	new[232]|giv[233]|giv[236]	_	_
27-70	4731-4735	days	place[232]|abstract[233]|time[236]	new[232]|giv[233]|giv[236]	_	_
27-71	4736-4737	.	_	_	_	_

#Text=The higher IE incidence in the North region may be due to the higher level of humidity experienced there compared to the Center or South regions of Spain .
28-1	4738-4741	The	abstract[238]	giv[238]	_	_
28-2	4742-4748	higher	abstract[238]	giv[238]	_	_
28-3	4749-4751	IE	object|abstract[238]	giv|giv[238]	coref	30-18
28-4	4752-4761	incidence	abstract[238]	giv[238]	_	_
28-5	4762-4764	in	abstract[238]	giv[238]	_	_
28-6	4765-4768	the	abstract[238]|place[240]	giv[238]|new[240]	_	_
28-7	4769-4774	North	abstract[238]|organization|place[240]	giv[238]|giv|new[240]	_	_
28-8	4775-4781	region	abstract[238]|place[240]	giv[238]|new[240]	_	_
28-9	4782-4785	may	_	_	_	_
28-10	4786-4788	be	_	_	_	_
28-11	4789-4792	due	_	_	_	_
28-12	4793-4795	to	_	_	_	_
28-13	4796-4799	the	abstract[241]	new[241]	_	_
28-14	4800-4806	higher	abstract[241]	new[241]	_	_
28-15	4807-4812	level	abstract[241]	new[241]	_	_
28-16	4813-4815	of	abstract[241]	new[241]	_	_
28-17	4816-4824	humidity	abstract[241]|abstract[242]	new[241]|new[242]	coref	31-14[262_242]
28-18	4825-4836	experienced	abstract[241]|abstract[242]	new[241]|new[242]	_	_
28-19	4837-4842	there	abstract[241]|abstract[242]	new[241]|new[242]	_	_
28-20	4843-4851	compared	_	_	_	_
28-21	4852-4854	to	_	_	_	_
28-22	4855-4858	the	place[243]	giv[243]	_	_
28-23	4859-4865	Center	place[243]	giv[243]	_	_
28-24	4866-4868	or	_	_	_	_
28-25	4869-4874	South	place|place[245]	giv|giv[245]	_	_
28-26	4875-4882	regions	place[245]	giv[245]	_	_
28-27	4883-4885	of	place[245]	giv[245]	_	_
28-28	4886-4891	Spain	place[245]|place	giv[245]|giv	_	_
28-29	4892-4893	.	_	_	_	_

#Text=These findings emphasized the importance of the site of acquisition .
29-1	4894-4899	These	abstract[247]	giv[247]	coref	31-4[261_247]
29-2	4900-4908	findings	abstract[247]	giv[247]	_	_
29-3	4909-4919	emphasized	_	_	_	_
29-4	4920-4923	the	abstract[248]	new[248]	_	_
29-5	4924-4934	importance	abstract[248]	new[248]	_	_
29-6	4935-4937	of	abstract[248]	new[248]	_	_
29-7	4938-4941	the	abstract[248]|place[249]	new[248]|new[249]	_	_
29-8	4942-4946	site	abstract[248]|place[249]	new[248]|new[249]	_	_
29-9	4947-4949	of	abstract[248]|place[249]	new[248]|new[249]	_	_
29-10	4950-4961	acquisition	abstract[248]|place[249]|abstract	new[248]|new[249]|new	ana	30-7
29-11	4962-4963	.	_	_	_	_

#Text=Indeed , to our knowledge , this is the first study to report a significant difference in IE rates in terms of location .
30-1	4964-4970	Indeed	_	_	_	_
30-2	4971-4972	,	_	_	_	_
30-3	4973-4975	to	_	_	_	_
30-4	4976-4979	our	person|abstract[252]	giv|new[252]	_	_
30-5	4980-4989	knowledge	abstract[252]	new[252]	_	_
30-6	4990-4991	,	_	_	_	_
30-7	4992-4996	this	abstract	giv	coref	30-9[254_0]
30-8	4997-4999	is	_	_	_	_
30-9	5000-5003	the	abstract[254]	giv[254]	_	_
30-10	5004-5009	first	abstract[254]	giv[254]	_	_
30-11	5010-5015	study	abstract[254]	giv[254]	_	_
30-12	5016-5018	to	abstract[254]	giv[254]	_	_
30-13	5019-5025	report	abstract[254]	giv[254]	_	_
30-14	5026-5027	a	abstract[254]|abstract[255]	giv[254]|new[255]	_	_
30-15	5028-5039	significant	abstract[254]|abstract[255]	giv[254]|new[255]	_	_
30-16	5040-5050	difference	abstract[254]|abstract[255]	giv[254]|new[255]	_	_
30-17	5051-5053	in	abstract[254]|abstract[255]	giv[254]|new[255]	_	_
30-18	5054-5056	IE	abstract[254]|abstract[255]|object|abstract[257]	giv[254]|new[255]|giv|giv[257]	_	_
30-19	5057-5062	rates	abstract[254]|abstract[255]|abstract[257]	giv[254]|new[255]|giv[257]	_	_
30-20	5063-5065	in	abstract[254]	giv[254]	_	_
30-21	5066-5071	terms	abstract[254]	giv[254]	_	_
30-22	5072-5074	of	abstract[254]	giv[254]	_	_
30-23	5075-5083	location	abstract[254]|abstract	giv[254]|new	ana	31-1
30-24	5084-5085	.	_	_	_	_

#Text=This corresponds with Blanco et al. ’ s findings , who demonstrated that increasing humidity is associated with greater Staphylococcus aureus colonization .
31-1	5086-5090	This	abstract	giv	_	_
31-2	5091-5102	corresponds	_	_	_	_
31-3	5103-5107	with	_	_	_	_
31-4	5108-5114	Blanco	person|abstract[261]	new|giv[261]	_	_
31-5	5115-5117	et	abstract[261]	giv[261]	_	_
31-6	5118-5121	al.	abstract[261]	giv[261]	_	_
31-7	5122-5123	’	abstract[261]	giv[261]	_	_
31-8	5124-5125	s	abstract[261]	giv[261]	_	_
31-9	5126-5134	findings	abstract[261]	giv[261]	_	_
31-10	5135-5136	,	abstract[261]	giv[261]	_	_
31-11	5137-5140	who	abstract[261]	giv[261]	_	_
31-12	5141-5153	demonstrated	abstract[261]	giv[261]	_	_
31-13	5154-5158	that	abstract[261]	giv[261]	_	_
31-14	5159-5169	increasing	abstract[261]|abstract[262]	giv[261]|giv[262]	coref	33-9[0_262]
31-15	5170-5178	humidity	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
31-16	5179-5181	is	abstract[261]	giv[261]	_	_
31-17	5182-5192	associated	abstract[261]	giv[261]	_	_
31-18	5193-5197	with	_	_	_	_
31-19	5198-5205	greater	event[265]	new[265]	_	_
31-20	5206-5220	Staphylococcus	object|object[264]|event[265]	giv|giv[264]|new[265]	coref|coref	32-3|32-4[0_264]
31-21	5221-5227	aureus	object[264]|event[265]	giv[264]|new[265]	_	_
31-22	5228-5240	colonization	event[265]	new[265]	_	_
31-23	5241-5242	.	_	_	_	_

#Text=Certainly , Staphylococcus aureus infections are more common in humid weather conditions .
32-1	5243-5252	Certainly	_	_	_	_
32-2	5253-5254	,	_	_	_	_
32-3	5255-5269	Staphylococcus	object|event[268]	giv|giv[268]	coref|coref	33-11|33-11[276_268]
32-4	5270-5276	aureus	object|event[268]	giv|giv[268]	coref	33-12
32-5	5277-5287	infections	event[268]	giv[268]	_	_
32-6	5288-5291	are	_	_	_	_
32-7	5292-5296	more	_	_	_	_
32-8	5297-5303	common	_	_	_	_
32-9	5304-5306	in	_	_	_	_
32-10	5307-5312	humid	abstract[269]|abstract[270]	giv[269]|new[270]	_	_
32-11	5313-5320	weather	abstract[269]|abstract[270]	giv[269]|new[270]	_	_
32-12	5321-5331	conditions	abstract[270]	new[270]	_	_
32-13	5332-5333	.	_	_	_	_

#Text=Wang et al. reported a similar correlation between humidity and Staphylococcus aureus infections .
33-1	5334-5338	Wang	person	new	_	_
33-2	5339-5341	et	_	_	_	_
33-3	5342-5345	al.	_	_	_	_
33-4	5346-5354	reported	_	_	_	_
33-5	5355-5356	a	abstract[272]	new[272]	_	_
33-6	5357-5364	similar	abstract[272]	new[272]	_	_
33-7	5365-5376	correlation	abstract[272]	new[272]	_	_
33-8	5377-5384	between	abstract[272]	new[272]	_	_
33-9	5385-5393	humidity	abstract[272]|abstract	new[272]|giv	_	_
33-10	5394-5397	and	abstract[272]	new[272]	_	_
33-11	5398-5412	Staphylococcus	abstract[272]|object|event[276]	new[272]|giv|giv[276]	_	_
33-12	5413-5419	aureus	abstract[272]|object|event[276]	new[272]|giv|giv[276]	_	_
33-13	5420-5430	infections	abstract[272]|event[276]	new[272]|giv[276]	_	_
33-14	5431-5432	.	_	_	_	_
